Agreements, Information Routines and Delegation of Tasks - SOP 1.13.a

Sist oppdatert: 25.07.2025
Utgiver: NorCRIN
Versjon: 2.0
Kopier lenke til dette emnet
Foreslå endringer/gi kommentarer

Changes from the Previous Version 

CT SOP version no 2.0

Changes from version 1.1: Updated according to ICH GCP R3. Details added re. reuirement for agreement with different trial committees, and PI's responsibility if tasks delegated to a service provider.

 

CT SOP version no 1.1.: Added template for Agreement for Support from External/Commercial Source - Template for use with commercial companies.

Responsibilities 

The sponsor has overall responsibility for ensuring that this SOP is followed.

 

The sponsor’s responsibilities shall be described in the quality system of the sponsor institution. Tasks are delegated according to SOP Roles and Responsibilities in clinical trials implemented in the institution.

 

The sponsor has overall responsibility for entering into a written agreement with all principal investigators/participating health facilities/other business parties in multicentre trials.

 

When a clinical trial has more than one sponsor, all co-sponsors shall in principle have the responsibilities of the sponsor if not otherwise described in a contract. Responsibilities for specific tasks will be defined in a written agreement (see "Co-sponsorship" under "Procedures" for details).

 

The sponsor may transfer any or all of the sponsor's trial-related duties and functions to a service provider such as a Contract Research Organisation (CRO), but the ultimate responsibility for the quality and integrity of the trial data always resides with the sponsor. The sponsor should ensure oversight of any trial-related duties and functions carried out on its behalf. Transfer of duties shall be specified in a written agreement.

 

The coordinating investigator has the responsibility for ensuring that tasks are carried out according to the requirements of this SOP.

Procedures 

Agreements

 

Agreements should clearly define the roles, activities and responsibilities for the clinical trial and be documented appropriately. (R3 10.2) 

Participating principal investigators/centres/pharmacies and other service departments should receive relevant documents such as the trial protocol, case report forms, and documentation on the investigational products (e.g. investigator's brochure) for review before agreements are made. The coordinating investigator should ensure that relevant updates of these documents are sent as soon as they are available. 

Agreements with internal and external parties should ensure access to all trial source data/documents and reports, as well as allow monitoring, auditing and inspections from the competent authorities. 

The principal investigator can delegate tasks to collaborators/staff involved in the trial within their own institution and/or can sign an agreement/contract with a service provider. 

 

Co-sponsorship

 

It is possible for the sponsor to share the sponsor responsibility and enter into a co-sponsorship agreement. This may be useful especially in international trials, see SOP International Trials

 

The co-sponsors shall agree, in a written contract, which of the following tasks will be the responsibility of only one sponsor and will not be shared between the different sponsors:

  • Compliance with a sponsor's obligations in the authorisation procedure (including any substantial modification and the procedure for the addition of a Member State concerned).
  • The contact point for receiving questions from subjects, investigators or any Member State concerned regarding the clinical trial and for replying to them.
  • Implementing corrective measures imposed by any of the Member states concerned.

 

The co-sponsors may also assign all remaining responsibilities in the written contract, but if they do not do this, the principle of joint responsibility applies.

 

Agreements between sponsor and sites 

 

All obligations/responsibilities should be described in written agreements with the participating health facility/centres for multicentre trials. The coordinating investigator shall ensure that the principal investigators responsible for the research at all participating centres are adequately informed about the trial, and that written agreements are made with all principal investigators/centres. Use of the Agreement Multicentre Trial is recommended. 

 

Agreements with service providers  

 

 It is recommended that the principal investigator has written agreements with hospital service providers which will provide services in the trial, e.g. pathology, radiography and laboratories. 

 

If applicable, the principal investigator must have written agreements with the pharmacy. The pharmacies usually wish to use their own agreements. 

The principal investigator may be supported by the sponsor in the identification of a suitable service provider(s); however, the investigator retains the final decision on whether the service provider intended to support the investigator is appropriate based on information provided by the sponsor. 

 

 Coordinating investigator should also have an agreement for monitoring and possibly other research support functions provided by Clinical Trials Units such as data management, statistics etc. Avtale med forskningsstøtte should be used. 

 

Agreements with funders 

 

Studies that receive funding, IMP or other support from a commercial company or similar, must have an agreement in place. It is recommended to use  Agreement for Support from External/Commercial Source for this purpose. The company may have their own agreement that must be used. The agreements should be reviewed by legal staff prior to signing, refer to institutional procedures. 

 

For trials receiving grants, the grant provider’s procedures should be followed. 

 

Establishing trial committees 

 

If trial committees such as steering committee, project group, scientific reference committee, etc. is established, an agreement or committee charter should be created, describing the committee’s mandate, decision making, frequency of meetings, face-to-face meetings or digital meetings, criteria for ad-hoc meetings, name and contact details for the committee members should be listed,and most importantly, publication rights and authorship for publications.  

 

For Data monitoring committees (or Data safety monitoring boards) see Data Monitoring Committee Charter.

 

Documentation 

The following should be filed in the ISF and TMF:

  • Signed agreements
  • The current documentation of the roles and allocation of trial-related tasks, e.g. updated delegation log (ISF only) and organisation chart at trial level (TMF only)
  • The CVs and GCP training certificate for all principal investigators (ISF and TMF) and other trial staff listed on the delegation log
  • For trials involving co-sponsors, the sponsor responsibility split (TMF only)

References 

External References

  • Regulation for clinical trials 536/2014 of The European Parliament and of the Council on clinical trials on medicinal products for human use.
  • ICH GCP R3 - especially section 3.6.
  • Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (OJ L 119, 4.5.2016, p. 1).

 

Internal References